The U.S. Food and Drug Administration issued more than 30 warning letters to telehealth and compounding firms for marketing compounded GLP‑1 copycats as comparable to approved products, signaling stepped‑up enforcement around semaglutide and tirzepatide imitators. The letters cite misleading claims and warned recipients to correct promotional language within 15 days or face legal action. Commissioner Marty Makary has publicly urged swift action against firms mass‑marketing copycat obesity drugs; the agency framed recent enforcement as a continuation of a September crackdown and said compounded drugs should not be positioned as substitutes for FDA‑approved medicines. The regulatory push has immediate commercial fallout: some vendors have paused or pulled products, while compounding pharmacies like Strive Pharmacy have said they will reintroduce variants after addressing compliance concerns, drawing scrutiny from both regulators and branded drugmakers. For industry audiences: the FDA’s approach increases legal and reputational risk for telehealth and compounding players in the obesity market and sharpens the distinction between approved GLP‑1 therapeutics and compounded alternatives—affecting distribution channels and commercial strategies across the sector.